External factors
| External factors: |
Rapamycin |
| Category: |
Chemical compounds |
| Phenotype: |
Chronic obstructive pulmonary disease |
| Experiment: |
SA-β-gal activity assay |
| Description: |
The PDL was lower for PA-SMCs and P-ECs from patients with COPD compared with those from controls. Rapamycin treatment consistently increased the PDLs of both PA-SMCs and P-ECs from patients with COPD and, to a lesser extent, from controls. Thus, PDLs for PA-SMCs and P-ECs from patients with COPD and controls no longer differed when both were treated with rapamycin. Rapamycin treatment also decreased the number of β-Gal–positive cells to similar values in the COPD and control groups.Rapamycin (10 nM) reduced IL-6, IL-8, and CCL2 levels in cells derived from COPD patients and from controls,although the effects varied among patients. |
Warning: Undefined variable $target_genes in
/data/html/Aging-ReG/public/browse_detail_2.php on line
385
Regulatory relationship
| R-EF-Pathway:
|
Downregulation |
| Official symbol(s): |
Warning: Undefined variable $name_all in /data/html/Aging-ReG/public/browse_detail_2.php on line 525
MTOR
|
| Pathway experiment: |
Western blot//ELISA |
| Pathway description: |
Rapamycin treatment increased the PDL in PA-SMCs from SM22-TSC1–/– mice, decreased the β-Gal–positive cell count, and inhibited mTOR activity . The increased mTOR signaling and higher cytokine levels measured 3 months after tamoxifen exposure in these mice returned to normal after rapamycin treatment. |
Aging network
Annotation:
The green line represents Upregulation.
The purple line represents Downregulation.
The orange line represents Activation.
The yellow line represents Inhibition.
The gray line represents Unclear.